C

Cencora

Distributes medicines and supports patient care

Field & Infusion Nurse - RN

Part-TimeUpdated on 10/20/2026
No salary listed
Mid
Whitbourne, NL, Canada+1 moreMore locations: Bay Roberts, NL, Canada
HybridTravel within the designated and surrounding IBUs and to clinics and homecare appointments is required.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • Relevant experience as a Registered Nurse is required.
  • One year of intravenous initiation experience is required.
  • Current registration with the licensing body and a current CPR certificate are required.
  • Experience in a critical care, emergency, acute care inpatient or outpatient, or homecare setting is required.
  • Proficiency in Microsoft Excel, Outlook, Word, and other applicable computer programs is required.
  • Access to an internet connection is required.
  • Knowledge of cell phones for making and confirming appointments or assignments and of fax machines is required.
  • Customer service skills are required for daily interactions with patients, family members, physicians, and clients.
  • Written and verbal communication skills are required.
  • Ability to work autonomously with little supervision as part of a larger team is required.
  • Ability to travel to clinics and homecare appointments within a set geographical boundary is required.
  • Critical thinking and its application are required.
  • Ability to communicate effectively both orally and in writing is required.
  • Interpersonal and leadership skills are required.
  • Organizational skills and attention to detail are required.
  • Time management and prioritization skills are required.
  • Ability to consistently meet deadlines is required.
  • Problem-solving skills and ability to resolve issues effectively and efficiently are required.
  • Presentation skills are required.
  • Ability to work independently in a self-directed manner is required.
  • Ability to adapt to a fast-paced environment is required.
  • A valid, non-expired, unrestricted driver's license and insurance coverage must be maintained.
  • The successful candidate may have daily contact with unilingual English-speaking customers, patients, or peers from cross-functional teams.
Responsibilities
  • Administer medications in patients’ homes, specialty clinics, and Physician Partnership clinic settings.
  • Assess and monitor patients before and after injection or infusion treatments as directed by program protocols.
  • Complete necessary documentation according to policies and procedures, College of Nurses direction, and Innomar ISO accreditation standards of practice.
  • Educate patients and caregivers, individually or in groups, based on product monographs and program protocols.
  • Report adverse events, serious adverse events, and product complaints in accordance with Innomar training and policies and procedures.
  • Maintain reliable availability based on the agreed employment arrangement to meet IBU and Nursing and clinics key performance indicators.
  • Communicate and work effectively with multidisciplinary teams, including case managers, physicians, pharmacy, scheduling, and other departments, to meet timelines for scheduling appointments and treatments.
  • Communicate with patients and caregivers to arrange appointments and drug delivery to homes and clinics.
  • Participate regularly in web-based team meetings and training sessions with the Business Area Manager, RNE, and Nurse Champion to maintain and enhance professional practice standards.
  • Participate in specialized client-related training as required.
  • Adhere to professional nursing standards prescribed by professional associations and Innomar.
  • Collaborate within the multidisciplinary healthcare team, providing oversight and delegating applicable tasks to RPN/LPN staff as authorized by the provincial College of Nurses.
  • Travel within the designated IBU and surrounding IBUs to meet operational needs.
  • Follow nursing and clinic standard operating procedures and work instructions.
  • Follow health and safety standards under the provincial Health and Safety Act.
  • Complete ongoing and annual education training within specified timeframes.
  • Perform other related duties and tasks as required by Innomar.
  • Be available for standby or on-call duty if required to meet service needs.
Desired Qualifications
  • Advanced knowledge of the pharmaceutical distribution industry is an asset.
  • Business and financial acumen are assets.
  • ACLS, PALS, MS and CVAA certifications, and central venous line or port experience are assets.

About the company

Cencora buys and distributes medicines for pharmacies, hospitals and physician practices, while helping drug manufacturers bring treatments to patients. Its businesses combine wholesale supply networks with specialty distribution for complex therapies and services that support prescribing and patient access. Customers order medicines through its distribution systems, and its teams manage sourcing, storage and delivery alongside pharmacy operations and manufacturer support. It earns revenue from pharmaceutical sales and fees for logistics and healthcare services. The parent company was formed in 2001 through the merger that created AmerisourceBergen, adopted the Cencora name in 2023, and is headquartered in Conshohocken, Pennsylvania.

Company Size

10,001+

Company Stage

IPO

Headquarters

Conshohocken, Pennsylvania

Founded

2001

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy contracts deepen customer ties: Cencora negotiates insurer agreements and handles administrative work through its managed-care networks.
  • Eligible US staff gain retirement support: Cencora counts student-loan payments toward its employer match, up to 4% of pay.
  • Drug demand expands sales: Cencora reported 5.1% quarterly revenue growth in August 2026, led by higher US volumes.

What critics are saying

  • Customer dependence concentrates risk: Walgreens and Boots supplied 25% of Cencora's fiscal 2025 revenue, reported in November 2025.
  • Legal liabilities tie up cash: Cencora's November 2025 filing recorded $4.3 billion in opioid settlements, payable over 13 years.
  • Warehouse work is physical: Cencora's day-shift associate listing requires repeated lifting up to 50 pounds and overtime availability.

What makes Cencora unique

  • Independent pharmacies get a shared brand: Cencora's Good Neighbor Pharmacy franchise supports their merchandising and store identity.
  • Specialty shipments use reusable packaging: Cencora's World Courier Cocoon containers combine passive temperature control with live location monitoring.
  • Medicines arrive ready for bedside checks: Cencora's American Health Packaging sells barcoded unit doses that support hospital scanning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Parental Leave
  • Adoption Assistance
  • Infertility Coverage
  • Family Planning Benefits
  • Behavioral Health Solutions
  • Professional Development Budget
  • Training Programs

Company News

Yahoo Finance
Oct 16th, 2026
Cencora stock: $332.8B revenue, 14.4% EPS growth and 50.2% ROIC

Cencora, the pharmaceutical distributor formerly known as AmerisourceBergen, has risen 6% to $341.69 per share over the past six months. The S&P 500 gained 9.7% in the same period. The New York Stock Exchange-listed company (NYSE:COR) connects drug manufacturers with healthcare providers and offers logistics, data analytics, and consulting services. It rebranded in 2023. Its revenue reached $332.8 billion over the past 12 months, giving it scale and bargaining power with suppliers. That matters in a low-margin, volume-driven business. Earnings per share grew at a 14.4% compound annual rate over five years, outpacing 10.2% annualised revenue growth. Its five-year average return on invested capital was 50.2%. The shares trade at 17.4 times forward earnings.

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.